GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,462.20
+17.20 (+1.19%)
As of 4:35PM BST. Market open.
Stock chart is not supported by your current browser
Previous Close1,445.00
Open1,445.00
Bid1,405.60 x 175400
Ask1,470.00 x 417900
Day's Range1,442.00 - 1,467.60
52 Week Range1,236.40 - 1,724.50
Volume8,279,830
Avg. Volume10,538,998
Market Cap71.537B
Beta1.03
PE Ratio (TTM)47.17
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.80 (5.63%)
Ex-Dividend Date2018-02-22
1y Target EstN/A
  • Currency weighs on GlaxoSmithKline first-quarter sales and earnings
    Reuters56 seconds ago

    Currency weighs on GlaxoSmithKline first-quarter sales and earnings

    LONDON (Reuters) - Drugmaker GlaxoSmithKline (GSK.L) reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles ...

  • Reuters8 minutes ago

    Currency weighs on GlaxoSmithKline Q1 sales and earnings

    Drugmaker GlaxoSmithKline reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles vaccine Shingrix. GSK's ...

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Reuters5 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO (Reuters) - Procter & Gamble's (PG.N) $4.2 billion deal for Merck's (MRCG.DE) vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.

  • Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
    Motley Fool5 days ago

    Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

    Which stock wins in a head-to-head matchup of these two big pharma companies?

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks6 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Novartis CEO feels heat on U.S. generics, Cosentyx drop
    Reuters6 days ago

    Novartis CEO feels heat on U.S. generics, Cosentyx drop

    Swiss drugmaker Novartis' (NOVN.S) first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.

  • Reuters6 days ago

    AI drug hunter BenevolentAI worth $2 billion after fund raising

    The aim is to use modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests. AI systems already play a central role in other high-tech sectors such as the development of driverless cars and facial recognition software.

  • Reuters7 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.

  • Reuters7 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis, and it showed benefits over other treatments in the study.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters7 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters7 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Industry fears disruption as EU excludes UK from drug approvals
    Reuters7 days ago

    Industry fears disruption as EU excludes UK from drug approvals

    A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients. The move confounds hopes for continued joint cooperation via the European Medicines Agency (EMA), at least during a transition or implementation period until the end of 2020 when the UK will remain closely tied to the European Union. Prime Minister Theresa May said in a speech on March 2 that London wanted to explore ways to keep Britain a part of EU agencies, such as the EMA.

  • Reuters7 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
    Bloomberg7 days ago

    Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria

    GlaxoSmithKline Plc and Novartis AG will contribute research funds to an almost $4 billion global effort to combat malaria as drug-resistant strains of the disease threaten to undo years of progress.

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily12 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks12 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
    Zacks12 days ago

    Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

    Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

  • Reuters13 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline (GSK.L) is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • Reuters13 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
    Zacks13 days ago

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

  • MarketWatch13 days ago

    U.K. stocks waver as traders remain wary over Syria conflict

    U.K. stocks struggle for direction on Thursday, as investors remain nervous over the potential for a military conflict in Syria and digested the latest Federal Reserve minutes.

  • Reuters13 days ago

    UK gene therapy firm Orchard plans stock offer after GSK deal

    Britain's Orchard Therapeutics, which has already raised more than $140 million (98.54 million pounds) to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines. Chief Executive Mark Rothera also told Reuters that an initial public offering (IPO) was an option beyond this next private financing move. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion acquisition of AveXis (AVXS.O) this week - but the rare disease products sold to Orchard are too niche for GSK as it refocuses its R&D efforts.

  • Financial Times13 days ago

    [$$] GSK sells rare disease gene therapy portfolio

    GlaxoSmithKline has offloaded its rare disease gene therapy portfolio to the biotechnology company Orchard Therapeutics, in exchange for a near-20 per cent stake in the two-year-old business. A sale of ...

  • Reuters13 days ago

    GSK divests rare disease gene therapy drugs to Orchard Therapeutics

    GlaxoSmithKline said on Thursday is was transferring its rare disease gene therapy drugs to Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals ...